Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
Masterjohn
Christopher
C
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy*; D023303:Oxazolidinones / Q000009:adverse effects* / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D014810:Vitamin E / Q000378:metabolism*
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D023303:Oxazolidinones; D011804:Quinolines; D014280:Triglycerides; D014810:Vitamin E; C483909:torcetrapib; C530884:anacetrapib